Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Oragenics stock | $0.7

Own Oragenics stock in just a few minutes.

Posted

Fact checked

Oragenics, Inc is a biotechnology business based in the US. Oragenics shares (OGEN) are listed on the NYSE MKT and all prices are listed in US Dollars. Oragenics employs 7 staff and has a market cap (total outstanding shares value) of USD$43.6 million.

How to buy shares in Oragenics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Oragenics Find the stock by name or ticker symbol: OGEN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Oragenics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$0.7, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Oragenics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Oragenics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Oragenics's share price?

Since the stock market crash in March caused by coronavirus, Oragenics's share price has had significant positive movement.

Its last market close was USD$0.7, which is 12.86% up on its pre-crash value of USD$0.61 and 59.09% up on the lowest point reached during the March crash when the shares fell as low as USD$0.44.

If you had bought USD$1,000 worth of Oragenics shares at the start of February 2020, those shares would have been worth USD$1,227.27 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,590.91.

Oragenics share price

Use our graph to track the performance of OGEN stocks over time.

Oragenics shares at a glance

Information last updated 2020-09-20.
Latest market closeUSD$0.7
52-week rangeUSD$0.36 - USD$1.84
50-day moving average USD$0.8276
200-day moving average USD$0.7038
Wall St. target priceUSD$2.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.511

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Available asset types Stock trade fee Option trade fee Annual fee
Vanguard
Stocks,Mutual funds,ETFs,Forex
$0
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
Stocks,Options,ETFs,Cryptocurrency
$0
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks,Bonds,Options,Mutual funds,Index funds,ETFs,Forex,Futures,Cash
$0
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
Stocks,Options,ETFs,Futures
$0
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
M1 Finance
M1 Finance
Stocks,ETFs
$0
$0
0%
A robo-advisor that puts you in the driver’s seat with fully-customizable portfolios.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Oragenics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Oragenics price performance over time

Historical closes compared with the last close of $0.7

1 week (2020-09-14) 3.24%
1 month (2020-08-21) -23.91%
3 months (2020-06-19) 34.62%
6 months (2020-03-20) 32.08%
1 year (2019-09-20) 38.59%
2 years (2018-09-21) -2.78%
3 years (2017-09-21) 94.77%
5 years (2015-09-21) -75.01%

Oragenics financials

Gross profit TTM USD$0
Return on assets TTM -83.52%
Return on equity TTM -150.31%
Profit margin 0%
Book value $0.029
Market capitalisation USD$43.6 million

TTM: trailing 12 months

Shorting Oragenics shares

There are currently 2.3 million Oragenics shares held short by investors – that's known as Oragenics's "short interest". This figure is 41.1% down from 4.0 million last month.

There are a few different ways that this level of interest in shorting Oragenics shares can be evaluated.

Oragenics's "short interest ratio" (SIR)

Oragenics's "short interest ratio" (SIR) is the quantity of Oragenics shares currently shorted divided by the average quantity of Oragenics shares traded daily (recently around 4.1 million). Oragenics's SIR currently stands at 0.57. In other words for every 100,000 Oragenics shares traded daily on the market, roughly 570 shares are currently held short.

However Oragenics's short interest can also be evaluated against the total number of Oragenics shares, or, against the total number of tradable Oragenics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oragenics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Oragenics shares in existence, roughly 40 shares are currently held short) or 0.0472% of the tradable shares (for every 100,000 tradable Oragenics shares, roughly 47 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oragenics.

Find out more about how you can short Oragenics stock.

Oragenics share dividends

We're not expecting Oragenics to pay a dividend over the next 12 months.

Have Oragenics's shares ever split?

Oragenics's shares were split on a 1:10 basis on 22 January 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oragenics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Oragenics shares which in turn could have impacted Oragenics's share price.

Oragenics share price volatility

Over the last 12 months, Oragenics's shares have ranged in value from as little as $0.36 up to $1.84. A popular way to gauge a stock's volatility is its "beta".

OGEN.US volatility(beta: 0.53)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Oragenics's is 0.5329. This would suggest that Oragenics's shares are less volatile than average (for this exchange).

Oragenics overview

Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring compound for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against dental caries, or tooth decay. Oragenics, Inc. has collaboration agreements with Precigen, Inc. and its subsidiary, Intrexon Actobiotics NV to develop AG013; and a license agreement with LPThera LLC to develop LPT3-04. It also has a process development and drug substance manufacturing agreement with Avid Bioservices, Inc. for coronavirus vaccine. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site